Trial Profile
A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 May 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Eribulin
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 26 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 30 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.